*Gtl2* (human *MEG3*) is expressed in the visceral yolk sac and embryonic ectoderm by early postimplantation mouse embryos \[[@r1]\]. During embryonic development, *Gtl2* transcripts are abundant in the paraxial mesoderm, certain regions of the central nervous system and in epithelial ducts \[[@r2]\]. Splice variants of *Gtl2* lack a consensus Kozak sequence for initiation of translation, suggesting that *Gtl2* encodes an RNA \[[@r1]\]. Normal pituitary tissue expresses high levels *Meg3* in contrast, *Meg3* expression is undetectable in human pituitary tumors and several cancer cell lines \[[@r3]\]. Further, transfection of a cancer cell line with *Meg3* inhibits its proliferation \[[@r4]\], indicating that *Meg3* transcripts function as tumor suppressors.

*Gtl2* is an imprinted gene that is expressed from the maternal allele \[[@r5]\]. Imprinted genes are regulated by parent-specific epigenetic modifications, including DNA methylation of the differentially methylated region (DMR). *Gtl2* is located within the *Dlk1--Dio3* paternally imprinted domain on chromosome 12 in mice and on chromosome 14 in humans \[[@r6]\]. This region includes three paternally expressed protein-coding genes (*Dlk1, Rtl1* and *Dio3*) and multiple maternally expressed ncRNAs (*Gtl2, Rtl1as, Rian* and *Mirg*) ([Fig. 1A](#fig_001){ref-type="fig"}Fig. 1.Teratoma induction and growth rate of MEFs using *Gtl2*(--/+) and WT embryos. (A) Schematic representation of the *Dlk1-Dio3* domain showing ncRNAs expressed from the maternally inherited chromosome and genes expressed from the paternal chromosome. The position of the imprinted genes is indicated by squares, vertical bars (snoRNAs) or triangles (miRNAs). (B) Pictures of E6.5 embryos (1 and 3, *Gtl2*(--/+); 2 and 4, WT) and teratomas with the kidney. (C) The box plot shows the distribution of weight in the *Gtl2*(--/+) and WT teratomas. \*\* P \< 0.05, Mann-Whitney test. The bar chart shows the weight range of the teratomas. (D, E) Histologic sections of *Gtl2*(--/+) (D) and WT (E) teratomas. The teratomas included neural tissues (ectoderm), muscle (mesoderm), cartilage (mesoderm) and a gut-like structure (endoderm). The asterisk indicates the gut-like structure, the larger diameter of which was over 1 cm. (F) The growth curve of WT and *Gtl2*(--/+) MEFs following a 3T3 protocol. The bar chart shows the average cell numbers for every 10 passages. \*\*\* P \< 0.01, unpaired *t*-test with Welch's correction.), which are regulated by the primary intergenic DMR (IG-DMR) and the postfertilization-derived secondary *Gtl2*-DMR \[[@r7]\]. A long transcript may span the *Gtl2*--*Mirg* domain \[[@r8]\]. Moreover, deleting *Gtl2* on the maternal allele decreases the expression of *Rtl1as, Rian* and *Mirg* that encode six small nucleolar RNAs and 59 microRNAs (miRNAs) (miRBase: http://www.mirbase.org/) \[[@r9]\].

The expression of the ncRNAs from the *Gtl2*--*Mirg* domain may correlate with the pluripotency of induced pluripotent stem cells, because the ncRNAs expressed by fully pluripotent cell lines are silenced in partially pluripotent cell lines \[[@r10], [@r11]\]. Moreover, miRNAs encoded by the *Dlk1-Dio3* domain are involved in tumorigenesis. For instance, overexpression of miRNAs by human hepatocellular carcinomas correlates with poor survival \[[@r12]\]. In contrast, expression of the miRNAs encoded by the *Dlk1-Dio3* domain is reduced in human epithelial ovarian cancer, which leads to increased tumor proliferation and shorter survival times \[[@r13]\]. These data suggest that both overexpression and repressed expression of the *Dlk1-Dio3* miRNAs are correlated with worsening tumor grade.

In the present study, we generated teratomas by engrafting scid mice with *Gtl2*^(--/+)^ embryos to gain a better understanding of the contribution of ncRNAs encoded by the *Dlk1--Dio3* domain to tumorigenesis. This teratoma formation assay is used to prove that *H19*, which is a paternally imprinted and maternally expressed ncRNA, acts *in vivo* as a tumor suppressor \[[@r14]\]. The results of histopathological and gene expression analyses showed that *Gtl2* deletion induced decreased expression of 28 miRNAs in the *Dlk1--Dio3* domain and led to increased cell proliferation and decreased expression of stem cell markers in the teratoma.

Materials and Methods {#s1}
=====================

Experimental animals
--------------------

*Gtl2* knockout mice \[[@r9]\] were maintained by mating with B6D2F1 (BDF1) mice for up to 10 generations. Immunodeficient scid mice were purchased from CLEA Japan. This study was approved by the Tokyo University of Agriculture Institutional Animal Care and Use Committee.

Teratoma formation
------------------

*Gtl2*^(--/+)^ and wild-type (WT) embryos at embryonic day (E) 6.5 were obtained by mating male WT (BDF1) and female *Gtl2*^(+/--)^ mice. To produce teratomas, E6.5 embryos were placed under the kidney capsules of scid mice. After four weeks, the teratomas were surgically removed, weighed and fixed or homogenized in TRIzol (Life Technologies, Carlsbad, CA, USA). Fixed sections were cut and stained with hematoxylin and eosin. For genotyping, DNAs were isolated from untreated teratomas.

Cell culture
------------

Mouse embryonic fibroblasts (MEFs) were harvested from *Gtl2*^(--/+)^ and WT E13.5 embryos, which were pooled separately for males and females (N = 2, each genotypes), and cultured according to the 3T3 protocol using 3 × 10^5^ cells seeded on a 10-cm diameter petri dish. The number of cells was counted every three days \[[@r15]\]. The cells were passaged at least 50 times in Dulbecco's Modified Eagle Medium (Life Technologies), 10% fetal bovine serum, penicillin and streptomycin at 37 C in an atmosphere containing 5% CO~2~.

miRNA array analysis
--------------------

Total RNAs extracted from the teratomas using TRIzol reagent were used for the miRNA array. The miRNAs were labeled using miRNA labeling regent (Agilent) and hybridized to mouse miRNA array v15 (Agilent). Images were scanned using an Agilent microarray scanner, and data were extracted with the supplied Feature Extraction software. The GeneSpring GX10 software was used to analyze the microarray results. The per-chip 90^th^ percentile method was used for normalization. We selected as a cutoff point a raw signal \> 50 for at least one sample.

Quantitative real-time RT-PCR
-----------------------------

Total RNA was extracted from teratomas with TRIzol reagent and treated with DNase, and cDNA was synthesized using SuperScript III and Oligo(dT) Primer (Life Technologies). Quantitative real-time PCR was performed using an ABI Real-Time PCR instrument. Seven (0.1221--0.9451 g) *Gtl2*^(--/+)^ and nine (0.0567--0.1823 g) WT teratoma samples were used for tests, respectively. The following primers were used for the analysis: P53F, TGAAACGCCGACCTATCCTTA; p53R, GGCACAAACACGAACCTCAAA; Oct4F, GTTGGA- GAAGGTGGAACCAA; Oct4R, TCT TCTGCTTCAGCAGCTTG; NanogF, CAGAAAAACCAGTGGTTGAAGACTAG; NanogR, GCAATGGATGCTGGGATACTC.

Statistical analysis
--------------------

All analyses were performed with PRISM (GraphPad, La Jolla, CA). The tests used for each analysis are noted in the figure legends.

Results {#s2}
=======

Teratoma induction and growth rate of MEFs
------------------------------------------

E6.5 *Gtl2*^(--/+)^ and WT embryos were placed under the kidney capsules of scid mice and examined for tumorigenicity *in vivo* after four weeks ([Fig. 1B](#fig_001){ref-type="fig"}). Eight teratomas with weight of more than 0.2 g were obtained by grafting *Gtl2*^(--/+)^ embryos ([Fig. 1C](#fig_001){ref-type="fig"}). This was significantly greater compared with the WT teratomas. Most of the teratomas weighed less than 0.2 g, and only 4 WT teratomas weighed over 0.2 g ([Fig. 1C](#fig_001){ref-type="fig"}). Histological analysis showed that the differentiation of the three germ layers and gut-like structures was more advanced in the *Gtl2*^(--/+)^ teratomas ([Fig. 1D and E](#fig_001){ref-type="fig"}) ([Supplementary Fig. S1](#pdf_001){ref-type="supplementary-material"}: online only).

We compared the proliferation *in vitro* of MEFs derived from the *Gtl2*^(--/+)^ and control embryos. The *Gtl2*^(--/+)^ and control MEFs grew at similar rates during the first several passages. In later passages, the growth rates of *Gtl2*^(--/+)^ MEFs surpassed those of the controls ([Fig. 1F](#fig_001){ref-type="fig"}). These data suggested that deleting *Gtl2* from the maternal allele enhanced cell proliferation *in vivo* and *in vitro.*

Expression of miRNAs by teratomas
---------------------------------

The miRNAs expressed from the *Dlk1-Dio3* domain may be involved in tumorigenesis \[[@r12], [@r13]\]. Using miRNA array analysis, we attempted to establish a link between the expression of specific miRNAs and the growth of the larger *Gtl2*^(--/+)^ teratomas (0.26--0.94 g). The miRNA array contained 80 miRNAs (including minor variants) encoded by the *Dlk1--Dio3* domain, and we detected expression of 31 miRNAs by the teratomas derived from WT embryos. Their expression levels in the *Gtl2*^(--/+)^ teratomas were decreased by a factor of at least 2, except for miR-299\* (1.9), miR-3072\* (1.3) and miR-494 (no difference) ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Expression by teratomas of miRNAs, *p53* and pluripotency markers. (A) Expression of miRNAs encoded within the *Dlk1-Dio3* domain. Twenty-eight miRNAs were decreased by a factor of at least 2 in the *Gtl2*(--/+) teratomas. (B) Twelve miRNAs mapping outside of the *Dlk1-Dio3* domain were differentially expressed (\> 2-fold) in the larger *Gtl2*(--/+) teratomas compared with the controls. Six ES cell-specific miRNAs and the tumor suppressor miR-18a were downregulated, and the oncogene miR-378, proliferation-related miR-196b and 3 tissue-specific miRNAs were upregulated in the larger *Gtl2*(--/+) teratomas. The vertical line represents the raw signal. The values represent means ± SD. One-way ANOVA followed by Fisher's LSD test was used to compare two *Gtl2*(--/+) groups with the control. \*\*\* P \< 0.01; \*\* P \< 0.05; \*P \< 0.1. (C) Expression of *p53* was downregulated (\*\* P \< 0.05, unpaired *t*-test with Welch's correction), and a trend toward a negative correlation was found between the teratoma weight and *p53* expression in the *Gtl2*(--/+) teratomas. P = 0.069, Spearman correlation test. (D) The level of expression of *Oct4* and *Nanog* in WT teratomas varied considerably and were significantly decreased in the *Gtl2*(--/+) teratomas. *Gapdh* was used as the internal control. \*\* P \< 0.05, unpaired *t*-test with Welch's correction., [Table 1](#tbl_001){ref-type="table"}Table 1.The number of miRNAs that expressed in the teratomas and differentially expressed by \> 2-fold in the growth promoted *Gtl2*^(--/+)^ teratomasLocation of miRNAsTotal numberDetectedup (\> 2-fold)down (\< 2-fold)All chromosome717212535Dlk1-Dio3 domain8031028) ([Supplementary Table S1](#pdf_001){ref-type="supplementary-material"}: online only). The target genes are known for approximately one half of these miRNAs, which act as tumor suppressors (Suppl Table S1). Therefore, we hypothesized that downregulation of their expression might affect the growth of the *Gtl2*^(--/+)^ teratomas. When we compared miRNA expression between the normal (0.12--0.13 g) and larger teratomas (0.26--0.94 g) in the *Gtl2*^(--/+)^, unexpectedly, there was no difference between expression levels of miRNAs encoded by the *Dlk1--Dio3* domain ([Fig. 2A](#fig_002){ref-type="fig"}). These findings suggested that the downregulation of the *Dlk1--Dio3* miRNAs was not enough to promote teratoma growth. Therefore, we focused on miRNAs located outside of the *Dlk1--Dio3* domain.

We detected ≥ 2-fold differences in expression levels between the larger *Gtl2*^(--/+)^ and WT teratomas for only 12 miRNAs that map to regions other than the *Dlk1--Dio3* domain ([Fig. 2B](#fig_002){ref-type="fig"}) ([Supplementary Tables S2 and S3](#pdf_001){ref-type="supplementary-material"}: online only). Among the downregulated miRNAs, miR-292-3p, 293, 295, 302a, 302c and 367 are embryonic stem cell markers \[[@r16]\], and miR-18a functions as a tumor suppressor \[[@r17]\]. Further, the expression levels of oncogenic miR-378, tumor-related miR-196b \[[@r18], [@r19]\] and tissue-specific miRNAs (miR-122, endoderm; miR-206, muscle; and miR-203, epidermis) were increased in the *Gtl2*^(-/+)^ teratomas \[[@r20],[@r21],[@r22]\]. Thus, the miRNA expression profile suggested the attenuation of stemness and increased differentiation of the *Gtl2*^(--/+)^ teratomas. Interestingly, miRNA expression levels tended to recover to the level of normal size *Gtl2*^(--/+)^ teratomas except for miR-292-3p, 293 and 295 in the miR-290/295 cluster ([Fig. 2B](#fig_002){ref-type="fig"}). In particular, expression of miR-378 and miR-196b returned to the control level, indicating that the dysregulation of these tumor-related miRNAs contributed to enlargement of the *Gtl2*^(--/+)^ teratomas.

Expression by teratomas of p53, pluripotency and differentiation-related markers
--------------------------------------------------------------------------------

To identify another cause of the teratoma enlargement, we analyzed the expression of *p53* by the *Gtl2*^(--/+)^ teratomas, because the human homolog (*MEG3*) of *Gtl2* activates *p53* and inhibits cell proliferation \[[@r4]\]. *Gtl2*^(--/+)^ teratomas expressed *p53* at significantly lower levels compared with WT-induced teratomas, which showed a trend, although not significant, toward a negative correlation with teratoma weight (r = --0.6429, P = 0.069) ([Fig. 2C](#fig_002){ref-type="fig"}). These data suggested that downregulation of *p53* expression contributed to the enhanced growth of *Gtl2*^(--/+)^ teratomas. To characterize the teratomas, we determined the expression levels of markers of pluripotency (*Oct4* and *Nanog*) and differentiation (*Sox17, Goosecoid, Brachyury, Sox1* and *Nestin*). There was no significant difference between the expression levels of the differentiation markers between the *Gtl2*^(--/+)^ and WT teratomas (data not shown). On the other hand, the levels of expression of *Oct4* and *Nanog* by WT teratomas varied considerably and were significantly decreased in the *Gtl2*^(--/+)^ teratomas, indicating that the pluripotency of *Gtl2*^(-/+)^ teratomas was limited ([Fig. 2D](#fig_002){ref-type="fig"}).

Discussion {#s3}
==========

The expression of *Dlk1--Dio3* ncRNAs is altered in several types of tumors and cancer cell lines in humans \[[@r3], [@r4]\]; however, it is unclear whether their expression pattern affects tumor formation or is changed by tumorigenesis. Deletion of the maternal *Gtl2* locus causes significantly decreased expression of downstream miRNAs in embryos \[[@r9]\]. Therefore, teratomas derived from *Gtl2*^(--/+)^ embryos serve as a model for evaluation of the role of *Dlk1--Dio3* ncRNAs in tumorigenesis. We show here that *Gtl2* and miRNAs located downstream control teratoma growth and stem cell markers *in vivo*.

Our analysis of the miRNA array reveals that 31 of 80 miRNAs encoded within the *Dlk1--Dio3* domain were expressed in WT teratomas, and the expression levels of 30 (except miR-494) were downregulated in *Gtl2*^(--/+)^ teratomas. Because the promoter of miR-494 is uniquely activated by the ERK1/2 pathway \[[@r23]\], its expression was likely unaffected by the deletion of *Gtl2*. Interestingly, mice injected with miR-494-transfected lung cancer cells produce larger tumors than controls \[[@r23]\] on the other hand, 13 of 28 miRNAs downregulated by the *Gtl2* deletion act as tumor suppressors, and their target genes are known (Table S1). For example, miR-410, which was highly expressed in WT teratomas, targets the MET proto-oncogene, and transfection with miR-410 inhibits proliferation in human glioblastoma cells \[[@r24]\]. Nevertheless, the expression levels of these tumor-related miRNAs were similar between the larger and normal size teratomas induced by *Gtl2*^(--/+)^ embryos ([Fig. 2A](#fig_002){ref-type="fig"}). This suggests that *Gtl2* deletion and the accompanying reduction of *Dlk1--Dio3* miRNAs are not enough to promote teratoma growth. Additionally, considering that the teratomas derived from the *H19*-deficient embryos clearly show enhanced growth \[[@r14]\], the tumor repressor activity of *Gtl2* may be moderate. According to the results of others \[[@r4]\], we reasoned that *p53* expression might account for the *Gtl2*^(--/+)^ teratoma size. This assumption was supported by findings that *p53* expression was significantly decreased in the *Gtl2*^(--/+)^ teratomas compared with the controls ([Fig. 2C](#fig_002){ref-type="fig"}). Moreover, when we analyzed miRNA loci mapping outside of the *Dlk1--Dio3* domain, we found that the levels of expression of 12 miRNAs by the larger *Gtl2*^(--/+)^ teratomas differed by a factor of ≥ 2 compared with controls. Among them, miR-378, miR-18a and miR-196b are involved in cell proliferation \[[@r17],[@r18],[@r19]\]. Previously published studies show that mice injected human glioblastoma cells transfected with miR-378 develop larger tumors than controls \[[@r18]\], overexpression of miR-196b induces proliferative activity in human leukemia cells \[[@r19]\], and growth is stimulated by transfection of anti-miR-18a in bladder cancer cell lines \[[@r17]\]. Therefore, increased expression levels of miR-378 and miR-196b as well as decreased expression of miR-18a correlate with the formation of larger teratomas in the *Gtl2*^(--/+)^ embryo-engrafted mice. Additionally, miR-378 and miR-196b expression recovered to the control level in the normal size *Gtl2*^(--/+)^ teratomas. MiR-378 targets the tumor suppressor genes *Sufu* and *Fus1*, whereas miR-196b targets the tumor suppressor genes *Fas* \[[@r18], [@r19]\]. These data suggested that dysregulation of these miRNAs promoted teratoma growth. MiR-378 and miR-196b are located in the intronic regions of *Ppargc1b* and *Hoxa9*, respectively. We hypothesized that *Ppargc1b* and *Hoxa9* were targeted by the *Dlk1-Dio3* miRNAs, and decreased expression of these miRNAs might induce overexpression of miR-378 and miR-196b in the *Gtl2*^(--/+)^ teratomas. As expected, the miRNA target prediction program microRNA.org \[[@r25]\] showed that *Ppargc1b* and *Hoxa9* are target genes of miR-543 (*Ppargc1b*), miR-154 (*Ppargc1b*) and miR-485 (*Hoxa9*), which are encoded by the *Dlk1-Dio3* domain ([Supplementary Fig. S2](#pdf_001){ref-type="supplementary-material"}: online only). Both miR-543 and miR-154 were expressed in the teratoma ([Fig. 2A](#fig_002){ref-type="fig"}), suggesting that dowregulation of these miRNAs induced overexpression of miR-378 encoded within *Ppargc1b* in the *Gtl2*^(--/+)^ teratomas. On the other hand, miR-485 expression was low in the teraotomas (average raw signal of 10.5 in WT and 2.8 in *Gtl2*^(--/+)^), and therefore, there might be a different mechanism that enhances miR-196b expression.

Interestingly, the expression levels of 6 ES cell-specific miRNAs in the miR-302/367 and miR-290/295 clusters \[[@r16], [@r26]\] were downregulated by factors of 5--16. The promoters of these two clusters are bound by *Oct4* and *Nanog* \[[@r27]\], the expression of which showed a significant decrease in the *Gtl2*^(--/+)^ teratomas ([Fig. 2D](#fig_002){ref-type="fig"}). It is reported that *Oct4* and *Nanog* bind around the upstream region of *Gtl2* and that these pluripotent markers regulate the *Dlk1-Dio3* imprinted domain \[[@r28]\]. Our study showed that *Gtl2* deletion induced repression of these transcription factors, indicating that the *Dlk1-Dio3* ncRNAs themselves may be involved in regulation of *Oct4* and *Nanog*. The expression levels of *Oct4* and *Nanog* may not affect teratoma size, as their levels of expression in four of the nine WT teratomas were lower than the average expression of the *Gtl2*^(--/+)^ teratomas. We expected accelerated differentiation of the *Gtl2*^(--/+)^ teratomas because of the lower expression of stemcell markers and advanced gut-like structures in the *Gtl2*^(--/+)^ teratomas. Though we were unable to detect a difference in the expression of genes encoding differentiation markers, tissue-specific miRNAs (miR-122, miR-206 and miR-203) showed increased expression in the *Gtl2*^(--/+)^ teratomas. The expression of these miRNAs is induced during differentiation \[[@r20],[@r21],[@r22]\], suggesting the possibility that differentiation is promoted in *Gtl2*^(--/+)^ teratomas.

Taken together, our present findings demonstrate that a proper expression dosage of *Dlk1--Dio3* ncRNAs is necessary to maintain the growth and expression of stem cell genes in teratomas. Thus, decreased expression levels of these miRNAs are associated with increased tumor proliferation \[[@r13]\]. Moreover, increased expression of them directly correlates with poor survival of patients with hepatocellular carcinoma \[[@r12]\].
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